NASDAQ:CABA - Cabaletta Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.25
  • Forecasted Upside: 1,027.66 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.18
▲ +0.015 (1.29%)

This chart shows the closing price for CABA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cabaletta Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CABA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CABA

Analyst Price Target is $13.25
▲ +1,027.66% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cabaletta Bio in the last 3 months. The average price target is $13.25, with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 1,027.66% upside from the last price of $1.18.

This chart shows the closing price for CABA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Cabaletta Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2022MizuhoLower Price TargetBuy$20.00 ➝ $10.00Low
5/16/2022HC WainwrightReiterated RatingBuy$11.00High
3/18/2022MizuhoLower Price TargetBuy$22.00 ➝ $20.00High
3/18/2022HC WainwrightLower Price TargetBuy$22.00 ➝ $11.00High
12/15/2021Morgan StanleyLower Price TargetOverweight$20.00 ➝ $15.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$17.00High
8/8/2021Evercore ISIReiterated RatingBuy$28.00High
6/29/2021MizuhoInitiated CoverageBuy$22.00High
3/17/2021HC WainwrightBoost Price TargetBuy$20.00 ➝ $22.00High
1/8/2021Chardan CapitalReiterated RatingBuy$21.00High
10/13/2020HC WainwrightInitiated CoverageBuy$20.00High
7/15/2020Morgan StanleyBoost Price TargetOverweight$19.00 ➝ $20.00Low
11/27/2019Morgan StanleyInitiated CoverageOverweight$19.00High
11/27/2019Evercore ISIInitiated CoverageOutperform$25.00High
11/19/2019Morgan StanleyInitiated CoverageOverweight$19.00 ➝ $19.00High
11/19/2019Evercore ISIInitiated CoverageOutperform$25.00High
11/19/2019CowenInitiated CoverageOutperformHigh
(Data available from 8/10/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/12/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/11/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/13/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/12/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cabaletta Bio logo
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $1.18
Low: $1.17
High: $1.18

50 Day Range

MA: $1.23
Low: $0.99
High: $1.61

52 Week Range

Now: $1.18
Low: $0.90
High: $14.95

Volume

466 shs

Average Volume

177,074 shs

Market Capitalization

$34.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Cabaletta Bio?

The following sell-side analysts have issued research reports on Cabaletta Bio in the last twelve months: HC Wainwright, Mizuho, Morgan Stanley, and Wells Fargo & Company.
View the latest analyst ratings for CABA.

What is the current price target for Cabaletta Bio?

4 Wall Street analysts have set twelve-month price targets for Cabaletta Bio in the last year. Their average twelve-month price target is $13.25, suggesting a possible upside of 1,027.7%. Wells Fargo & Company has the highest price target set, predicting CABA will reach $17.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $10.00 for Cabaletta Bio in the next year.
View the latest price targets for CABA.

What is the current consensus analyst rating for Cabaletta Bio?

Cabaletta Bio currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CABA will outperform the market and that investors should add to their positions of Cabaletta Bio.
View the latest ratings for CABA.

What other companies compete with Cabaletta Bio?

How do I contact Cabaletta Bio's investor relations team?

Cabaletta Bio's physical mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The company's listed phone number is 267-759-3100 and its investor relations email address is [email protected] The official website for Cabaletta Bio is www.cabalettabio.com. Learn More about contacing Cabaletta Bio investor relations.